Harmony Biosciences (HRMY) Competitors $38.77 -0.77 (-1.95%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$38.77 0.00 (0.00%) As of 01/31/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HRMY vs. ROIV, ASND, BPMC, BBIO, LNTH, RVMD, LEGN, ELAN, NUVL, and CYTKShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Lantheus (LNTH), Revolution Medicines (RVMD), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Roivant Sciences Ascendis Pharma A/S Blueprint Medicines BridgeBio Pharma Lantheus Revolution Medicines Legend Biotech Elanco Animal Health Nuvalent Cytokinetics Roivant Sciences (NASDAQ:ROIV) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability. Does the media prefer ROIV or HRMY? In the previous week, Harmony Biosciences had 13 more articles in the media than Roivant Sciences. MarketBeat recorded 18 mentions for Harmony Biosciences and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.76 beat Harmony Biosciences' score of 0.67 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ROIV or HRMY? Roivant Sciences has higher earnings, but lower revenue than Harmony Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$129.13M62.74$4.35B$5.651.97Harmony Biosciences$582.02M3.80$128.85M$2.1118.37 Does the MarketBeat Community believe in ROIV or HRMY? Harmony Biosciences received 6 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 67.86% of users gave Harmony Biosciences an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% Harmony BiosciencesOutperform Votes5767.86% Underperform Votes2732.14% Do institutionals & insiders have more ownership in ROIV or HRMY? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, ROIV or HRMY? Roivant Sciences has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Do analysts rate ROIV or HRMY? Roivant Sciences currently has a consensus target price of $17.93, suggesting a potential upside of 61.08%. Harmony Biosciences has a consensus target price of $55.00, suggesting a potential upside of 41.86%. Given Roivant Sciences' higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ROIV or HRMY more profitable? Roivant Sciences has a net margin of 3,827.42% compared to Harmony Biosciences' net margin of 17.98%. Harmony Biosciences' return on equity of 23.16% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences3,827.42% -14.65% -13.19% Harmony Biosciences 17.98%23.16%14.24% SummaryHarmony Biosciences beats Roivant Sciences on 10 of the 18 factors compared between the two stocks. Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.21B$6.86B$5.56B$9.11BDividend YieldN/A2.90%5.31%3.98%P/E Ratio18.379.9789.9918.25Price / Sales3.80287.751,242.1483.63Price / Cash14.8873.5045.9637.70Price / Book4.865.275.124.71Net Income$128.85M$136.98M$111.09M$224.24M7 Day Performance2.00%-0.62%2.38%1.08%1 Month Performance12.67%0.15%3.20%1.51%1 Year Performance23.91%7.68%24.70%20.44% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.6231 of 5 stars$38.77-1.9%$55.00+41.9%+22.9%$2.21B$582.02M18.37200Insider TradeROIVRoivant Sciences3.0968 of 5 stars$11.13-0.3%$17.93+61.0%+11.3%$8.09B$124.79M1.97860Analyst UpgradeASNDAscendis Pharma A/S3.4336 of 5 stars$127.53-0.5%$192.07+50.6%+0.6%$7.75B$288.08M-15.81640Upcoming EarningsAnalyst ForecastShort Interest ↓BPMCBlueprint Medicines0.9712 of 5 stars$114.51-0.4%$123.56+7.9%+41.5%$7.26B$249.38M-54.19640Short Interest ↑BBIOBridgeBio Pharma4.0242 of 5 stars$36.69-2.4%$48.08+31.1%-0.2%$6.93B$9.30M-15.22400Insider TradeShort Interest ↑News CoverageLNTHLantheus4.5338 of 5 stars$98.76+1.3%$131.86+33.5%+78.1%$6.88B$1.30B16.47700Short Interest ↑News CoverageRVMDRevolution Medicines4.4555 of 5 stars$40.82-0.4%$66.25+62.3%+54.8%$6.87B$11.58M-11.37250LEGNLegend Biotech3.2098 of 5 stars$36.67-0.6%$79.50+116.8%-30.8%$6.70B$285.14M-38.601,800Short Interest ↓ELANElanco Animal Health4.3179 of 5 stars$12.04-0.4%$16.43+36.5%-18.4%$5.95B$4.42B30.099,300Analyst ForecastNews CoverageNUVLNuvalent2.4303 of 5 stars$82.83+0.7%$112.36+35.6%+14.2%$5.89BN/A-23.8840Insider TradePositive NewsCYTKCytokinetics3.9289 of 5 stars$49.98-1.5%$82.79+65.7%-36.7%$5.89B$7.53M-9.27250 Related Companies and Tools Related Companies Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Lantheus Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Nuvalent Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HRMY) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
